Clinical trial

Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC

NCT04087473

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2019-08-23

PhaseN/A

Study timeline

Study start (actual)2019-08-23Date precision: day

Registry last updated2026-05-13

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-small Cell Lung Cancerunresolved

ALK-Positive Lung Cancerunresolved

Interventions

Sponsors & collaborators

National Cancer Centre, Singaporelead sponsor

Guardant Health AMEA, Inc.collaborator

Mapped research locations

SeoulSouth Korea2 SingaporeSingapore1 Hong KongHong Kong1 Kuala LumpurMalaysia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04087473 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.